CSIMarket
 
Applied Therapeutics Inc   (APLT)
Other Ticker:  
 
 
Price: $5.3000 $-0.44 -7.666%
Day's High: $6.2 Week Perf: -0.19 %
Day's Low: $ 5.27 30 Day Perf: 81.51 %
Volume (M): 1,465 52 Wk High: $ 6.20
Volume (M$): $ 7,762 52 Wk Avg: $1.95
Open: $5.76 52 Wk Low: $0.76



 Market Capitalization (Millions $) 481
 Shares Outstanding (Millions) 91
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Applied Therapeutics Inc
Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of serious diseases. The company aims to address unmet medical needs by targeting specific pathways to restore health and improve patient outcomes. Applied Therapeutics Inc utilizes a multi-disciplinary approach, combining expertise in drug development, clinical pharmacology, and translational medicine to advance its pipeline of therapeutic candidates. The company's research and development efforts primarily focus on therapies for glycobiology-related diseases, such as diabetic complications and rare genetic disorders.


   Company Address: 545 Fifth Avenue New York 10017 NY
   Company Phone Number: 220-9226   Stock Exchange / Ticker: NASDAQ APLT
   APLT is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Results for Govorestat (AT-007): A Potential Breakthrough in the Treatment of SORD Deficiency

Published Thu, Feb 15 2024 12:01 PM UTC

In the field of pharmaceutical sciences, continuous research and development efforts to find better treatment options for rare genetic disorders have led to significant advancements. In this context, Applied Therapeutics Inc has recently announced positive results from a 12-month interim analysis of Govorestat (AT-007) in their ongoing INSPIRE Phase 3 Trial for Sorbitol Dehy...

Applied Therapeutics Inc

Applied Therapeutics Inc. Struggles to Achieve Stability and Profitability in the Pharmaceutical Industry

r/>As the reporting season for the third quarter of 2023 progresses, several companies have disclosed their financial results. Among them is Applied Therapeutics Inc. (APLT), a constituent of the Major Pharmaceutical Preparations sector. The company recently announced an operating loss of $-15.495 million, marking an improvement from the previous year's third-quarter operating loss of $-19.356 million. However, despite this incremental positive change, APLT's overall financial health remains concerning, as evidenced by its widened net loss of $-42.370 million compared to $-19.101 million in the same period last year.
Building Up a Business Model:
Like many small businesses in the stock market, Applied Therapeutics Inc. is still in the process of refining and expanding its business model. However, given the highly competitive nature of the pharmaceutical industry, the need for efficient business practices becomes even more critical. Without steady growth and profitability, it becomes increasingly challenging for companies like APLT to reach the next level and establish themselves as significant players in the market.

Applied Therapeutics Inc

Improved Financial Performance Reflected in Applied Therapeutics Inc.'s Q2 2023 Report, With Operating Shortfall Enhanced to $-21.521 Million

Applied Therapeutics Inc. is a company in the Major Pharmaceutical Preparations sector that recently reported its earnings for the period covering April to June 30, 2023. The company issued an operating shortfall of $-17.176 million during this time, representing an increase compared to the second quarter of 2022, where the operating shortfall stood at $-21.521 million. This indicates a positive trend for Applied Therapeutics Inc.
As a developing business, it is crucial for Applied Therapeutics Inc to operate cost-effectively in order to progress and reach the next stage of its growth. The management is actively seeking different corporate strategies to expand its product line and improve its financial performance.

Applied Therapeutics Inc

Applied Therapeutics Inc Sees Double-Digit Revenue Growth, Narrowing Net Shortfall

Major Pharmaceutical Preparations Company Reports Strong Revenue Growth, while Applied Therapeutics Inc Reports a Narrower Net Shortfall
In the most recent fiscal period, Major Pharmaceutical Preparations Company (MPPC) has reported a substantial increase in its revenues, while Applied Therapeutics Inc (ATI) has managed to narrow down its net shortfall significantly.
According to the financial reports, MPPC revealed $10.66 million in revenue during the most recent fiscal period, which is an excellent performance by the pharmaceutical giant. The company has been able to capitalize on the growing demand for its products, which includes both prescription and over-the-counter medications. This growth in revenue can be attributed to the company's focus on research and development, which has enabled the company to introduce new and innovative products that meet the needs of its customers.
On the other hand, ATI reported a net shortfall of $-10.137 million in the most recent fiscal period, which is a significant improvement compared to the $-23.121 million net shortfall from the same reporting season a year ago. This reduction in net shortfall can be attributed to the company's focus on reducing its costs and improving its efficiency.
ATI has been investing heavily in its research and development efforts, which has resulted in the development of several promising drugs for various medical conditions. The company is expected to continue this trend in the future, with its next financial report scheduled to be released on August 11, 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com